Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

228M-1

Sigma-Aldrich

BG8, LewisY (F3) Mouse Monoclonal Antibody

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Kod UNSPSC:
12352203
NACRES:
NA.41

pochodzenie biologiczne

mouse

Poziom jakości

100
500

białko sprzężone

unconjugated

forma przeciwciała

culture supernatant

rodzaj przeciwciała

primary antibodies

klon

F3, monoclonal

opis

For In Vitro Diagnostic Use in Select Regions (See Chart)

Postać

buffered aqueous solution

reaktywność gatunkowa

human

opakowanie

vial of 0.1 mL concentrate (228M-14)
vial of 0.5 mL concentrate (228M-15)
bottle of 1.0 mL predilute (228M-17)
vial of 1.0 mL concentrate (228M-16)
bottle of 7.0 mL predilute (228M-18)

producent / nazwa handlowa

Cell Marque™

metody

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:50

izotyp

IgM

kontrola

adenocarcinoma of lung

Warunki transportu

wet ice

temp. przechowywania

2-8°C

wizualizacja

cytoplasmic

informacje o genach

human ... F3(2152)

Powiązane kategorie

Opis ogólny

Blood group antigens have been examined as potential discriminators between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). Lewisy is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and its ability to distinguish between PACA and EM was first reported by Jordon and colleagues in 1989. Three groups have since reported their results. These studies included 231 cases of PACA and 197 cases of EM. Sensitivity and specificity for PACA were both 93%. Yaziji H et al. reported a sensitivity of nonmesothelial antigens for adenocarcinoma as organ dependent, with BG8 performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. They concluded using logical regression analysis that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from adenocarcinoma from a variety of sources (lung, ovary, breast, stomach).

Jakość


IVD
IVD
IVD
RUO

Powiązanie

BG8 Positive Control Slides, Product No. 228S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Postać fizyczna

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Uwaga dotycząca przygotowania

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Inne uwagi

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informacje prawne

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.

Nie możesz znaleźć właściwego produktu?  

Wypróbuj nasz Narzędzie selektora produktów.

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

N G Ordóñez
The American journal of surgical pathology, 24(4), 598-606 (2000-04-11)
The distinction between malignant pleural mesotheliomas and adenocarcinomas, particularly those originating in the lung, is a difficult diagnostic problem that can be facilitated by the use of immunohistochemical markers. In this study, the immunoreactivity of thyroid transcription factor-1 (TTF-1), E-cadherin
B Davidson et al.
Virchows Archiv : an international journal of pathology, 435(1), 43-49 (1999-08-04)
The detection of malignant cells in pleural, peritoneal, and pericardial fluids of cancer patients marks the presence of metastatic disease and is associated with a grave prognosis. We evaluated five epithelial markers for the detection of cancer cells in 94
Alberto M Marchevsky et al.
Applied immunohistochemistry & molecular morphology : AIMM, 15(2), 140-144 (2007-05-26)
There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for
Nelson G Ordóñez
The American journal of surgical pathology, 27(8), 1031-1051 (2003-07-29)
A large number of immunohistochemical markers that can facilitate the distinction between epithelioid pleural mesotheliomas and pulmonary peripheral adenocarcinomas have recently become available. The aim of this study is to compare the value of these new markers with others that
J E King et al.
Histopathology, 48(3), 223-232 (2006-01-25)
Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej